Phathom Pharmaceuticals Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Phathom Pharmaceuticals Inc
TickerPHAT
CIK #0001783183
CUSIP71722W107
SectorLife Sciences - Pharmaceutical Preparations
Address2150 E Lake Cook Road, Suite 800, Buffalo Grove, IL 60089
Source [EDGAR]
CIK Filing 2011 - 2024
[0001783183] 10-K
[0001783183] 10-Q
[0001783183] 3
[0001783183] 4
[0001783183] 5
[0001783183] 8-K
[0001783183] SC 13D
[0001783183] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Carlyle Group Inc Phathom Pharmaceuticals Inc [2023-03-09] 6.7
Flynn James E Phathom Pharmaceuticals Inc [2022-09-23] 5.81
Avidity Partners Management LP Phathom Pharmaceuticals Inc [2022-02-14] 6.0
Vanguard Group Inc Phathom Pharmaceuticals Inc [2022-02-10] 6.14
Janus Henderson Group PLC Phathom Pharmaceuticals Inc [2020-02-14] 6.0
Invesco Ltd Phathom Pharmaceuticals Inc [2020-02-13] 8.6
Yamada Tadataka Phathom Pharmaceuticals Inc [2020-02-10] 6.9
Medicxi Growth I LP Phathom Pharmaceuticals Inc [2020-02-10] 8.2
Socks David A Phathom Pharmaceuticals Inc [2020-02-10] 6.9
RA Capital Management LP Phathom Pharmaceuticals Inc [2019-11-08] 12.6
Takeda Pharmaceutical Co Ltd Phathom Pharmaceuticals Inc [2019-11-06] 24.7
Frazier Life Sciences IX LP Phathom Pharmaceuticals Inc [2019-11-06] 25.1
Form 3/4/5 Filer 2011 - 2024
Phathom Pharmaceuticals, Inc.
Parikh Asit
Henderson Molly
Stenhouse Mark
Socks David A
Fields Heidi
Karbe Frank
Cola Michael F
Topper James N
Nabulsi Azmi
Curran Terrie
Takeda Pharmaceutical Co Ltd
Guzzo Anthony J.
Yamada Tadataka
RA Capital Healthcare Fund LP
RA Capital Management LP
Shah Rajeev M.
Kolchinsky Peter
Branning Todd P.
Fhmls IX LLC
Fhmls IX LP
Frazier Life Sciences IX, L.P.
Heron Patrick J
Edwards Jonathan S.
Slavinsky Christopher W.
Kohli Aditya
Form 13F Holdings
Firm Period DFND Voting Shares
Frazier Life Sciences Management LP [2023-03-31] SOLE 8,407,152.0 8,407,152.0
Carlyle Group Inc. [2023-03-31] DFND 0.0 2,935,106.0
Medicxi Ventures Management (Jersey) Ltd [2023-03-31] SOLE 2,484,274.0 2,484,274.0
Invesco Ltd. [2023-03-31] DFND 0.0 2,181,672.0
Avidity Partners Management LP [2023-03-31] SOLE 2,048,600.0 2,048,600.0
Ensign Peak Advisors, Inc [2023-03-31] SOLE 1,761,191.0 1,761,191.0
BlackRock Inc. [2023-03-31] SOLE 1,613,718.0 1,632,910.0
683 Capital Management LLC [2023-03-31] DFND 1,325,500.0 1,325,500.0
Vanguard Group Inc [2023-03-31] SOLE 0.0 1,118,262.0
Newtyn Management LLC [2023-03-31] SOLE 682,027.0 682,027.0
GW&K Investment Management LLC [2023-03-31] SOLE 598,848.0 598,848.0
Gilder Gagnon Howe & Co LLC [2023-03-31] DFND 0.0 553,829.0
Opaleye Management Inc [2023-03-31] SOLE 496,000.0 496,000.0
State Street Corp [2023-03-31] DFND 426,607.0 463,743.0
Geode Capital Management LLC [2023-03-31] DFND 448,611.0 448,611.0
StepStone Group LP [2023-03-31] DFND 422,085.0 422,085.0
Susquehanna International Group LLP [2023-03-31] DFND 146,416.0 338,116.0
Bank of America Corp /DE/ [2023-03-31] DFND 32,959.0 253,485.0
Simplify Asset Management Inc [2023-03-31] SOLE 237,935.0 237,935.0
Citadel Advisors LLC [2023-03-31] DFND 234,084.0 234,084.0
Northern Trust Corp [2023-03-31] DFND 8,287.0 212,901.0
Bioimpact Capital LLC [2023-03-31] SOLE 212,615.0 212,615.0
SilverArc Capital Management LLC [2023-03-31] SOLE 200,000.0 200,000.0
Charles Schwab Investment Management Inc [2023-03-31] SOLE 171,607.0 171,607.0
JPMorgan Chase & Co [2023-03-31] DFND 114,699.0 133,587.0
Nuveen Asset Management LLC [2023-03-31] DFND 108,284.0 108,284.0
UBS OConnor LLC [2023-03-31] DFND 100,093.0 100,093.0
State of Wisconsin Investment Board [2023-03-31] SOLE 95,167.0 95,167.0
Morgan Stanley [2023-03-31] DFND 92,046.0 93,698.0
Atom Investors LP [2023-03-31] SOLE 86,607.0 86,607.0
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com